Browsing by Author "Çilli, Aykut"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Item Demographic, clinical and management characteristics of newly diagnosed COPD patients in Turkey: A real-life study(Dove Medical Press Ltd., 2020) Suerdem, Mecit; Günen, Hakan; Akyıldız, Levent; Çilli, Aykut; Özlü, Tevfik; Abadoğlu, Öznur; Bayram, Hasan; Cimrin, Arif Hikmet; Gemicioğlu, Bilun; Mısırlıgil, Zeynep; Uzaslan, Esra; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Bölümü; AAI-1004-2021; 8761653500Purpose: In order to determine the clinical and sociodemographic characteristics of newly diagnosed treatment-naïve asthma and COPD patients in Turkey, a multicenter study in 2012 was initiated . We aimed to investigate the characteristics and therapies of COPD patients in the original study in more detail. Patients and Methods: This nation-wide, multicentric, non-interventional, prospective, real-life observational cohort study was conducted in 122 centers. The newly diagnosed patients were not receiving any treatment before the recruitment. Their general characteristics, the combined GOLD 2011 COPD categories and exacerbation histories were noted. The patients were followed up with 3 voluntary visits for 1 year. Their adherence to the inhaled treatment according to GOLD 2011 was evaluated during follow-up visits. Results: The study included 776 COPD patients. Their mean age was 59.4±9.1 years, and 11.9% of the patients were female. 35.1% of the patients were in the GOLD 2011 C and D category. 12.6% are frequent exacerbators, and 52.8% had at least one comorbid condition. 71.8% overtreatment rate was detected. Their attendance rates for three follow-up visits became 55.9%, 32.9% and 18.7%, respectively. The adherence rate to the treatment was measured as 81.9%. Conclusion: Although these patients were diagnosed for the first time, the GOLD C and D categories and frequent exacerbator phenotype were found at a high rate. They were usually prescribed an overtreatment regimen. We think that newly diagnosed COPD patients should be evaluated carefully, and best effort should be made to treat these patients in accordance with the recommendations of the major COPD guidelines.Item Effects of vaccination on clinical presentation of community acquired pneumonia (CAP)(European Respiratory Society Journals, 2013-09) Çilli, Aykut; Kılınç, Oğuz; Coşkun, Ayşin Sakar; Sayıner, Abdullah; Hazar, Armağan; Köktürk, Nurdan; Filiz, Ayten; Polatlı, Mehmet; Çetinoğlu, Ezgi Demirdöğen; Uzaslan, Esra; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; AAI-1004-2021Item National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey(Wiley, 2011-06) Dursun, Adile Berna; Bavbek, Sevim; Mısırlıgil, Zeynep; Erdener, F.; Büyüköztürk, Suna; Aydın, Ömür; Gemicioğlu, Bilun; Bayrak, P.; Erkekol, Ferda Öner; Yıldırım, Zeki; Çilli, Aykut; Boz, Bingol A.; Alpaydın, Özgen A.; Karakoç, Bingol G.; Görgüner, Metin; Karakaya, Gül; Işık, Rüveyda; Bakırtaş, Arzu; Sapan, Nihat; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.Item Newly diagnosed asthma in the elderly: Is it really different?(Mosby-Elsevier, 2014-02) Gemicioğlu, Bilun; Abadoğlu, Öznur; Akyıldız, Levent; Bayram, Hasan; Çilli, Aykut; Cimrin, Arif; Günen, Hakan; Mısırlıgil, Zeynep; Özlü, Tevfik; Suerdem, Mecit; Uzaslan, Esra; Uludağ Üniversitesi/Tıp Fakültesi.; AAI-1004-2021Item Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation(Taylor & Francis, 2017) Sayıner, Abdullah; Çilli, Aykut; Kılınç, Oğuz; Sakar Coşkun, Aysın; Hazar, Armağan; Köktürk, Nurdan; Filiz, Ayten; Polatlı, Mehmet; Taşbakan, Sezai; Karaboğa, Burcu; Çetinoğlu, Ezgi Demirdöğen; Uzaslan, Esra; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; AAI-1004-2021; 14062849300; 8761653500Background: Previous reports have shown that vaccination rates of adult at-risk populations are low in Turkey. There are differing reports with regards to the effectiveness of the influenza and the pneumococcal polysaccharide vaccine (PPSV23) on the clinical outcomes of community acquired pneumonia (CAP). The purpose of this study was to analyze the influenza (FV) and pneumococcal vaccination (PV) status, the factors that influence the receipt of influenza/pneumococcal vaccine and the effects of prior vaccination on the clinical outcomes in adults hospitalized with CAP. Patients and Methods: Patients hospitalized with CAP between March 2009 and October 2013 and registered at the web-based Turkish Thoracic Society Pneumonia Database (TURCAP) were included in this multicentric, observational study. Of a total of 787 cases, data were analyzed for 466 patients for whom self-reported information on PV and FV was available. Results: In this adult population with CAP, the vaccination rate with both the pneumococcal and influenza vaccines was found to be 6%. Prior FV was found to be the sole variable that was associated with the receipt of PV [OR 17.8, 95% CI (25-75:8.56-37.01), p < 0.001]. Conversely, being vaccinated with PPSV23 was the only predictor of receipt of FV [OR 18.1, 95% CI (25 - 75:8.75 - 37.83), p < 0.001]. Compared to the unvaccinated cases, the chest radiograms of the vaccinated patients revealed less consolidation. The latter also reported fatigue, muscle pain and gastrointestinal symptoms less frequently. Although there was a trend for lower 30-day mortality and for lower rates of intensive care unit (ICU) admission, these did not reach statistical significance. A pneumonia severity index (PSI) score >= 90, CURB-65 score >= 3 and multilobar involvement, but not the vaccination status, were identified as independent determinants of ICU admission. Conclusions: This study showed that, among patients hospitalized with CAP, the FV and/or PV rates are low. Prior vaccination does not appear to significantly affect the clinical outcomes.Publication Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis(Elsevier, 2021-11-24) Çilli, Aykut; Uzer, Fatih; Sevinç, Can; Coskun, Funda; Ursavaş, Ahmet; Öner, Sukriye; Köse, Firat; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Ursavas, Ahmet; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-3604-8826; AAI-3169-2021; AAD-1271-2019Background: The antifibrotic drugs nintedanib and pirfenidone reduce disease progression in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching first-line antifibrotic drug may required in IPF due to disease progression or intolerable adverse effects. The aim of this study was to assess the safety and efficacy of second-line antifibrotic treatment in patients with IPF.Material and methods: This retrospective, multicenter study was conducted at three referral interstitial lung disease centers who received first-line antifibrotics more than one month and switched the treatment to a second line antifibrotic agent during January 2016-June 2021. The drug's safety was evaluated based on the type of adverse effect. Disease progression was defined as an absolute decline in FVC of >10% within 12 months with or without radiological progression.Results: Among 629 consecutive patients with IPF, 66 patients switched antifibrotics. The median duration of antifibrotics was 13 (1-41) months prior to the switch, and 14 (2-42) months after the switch. The mean age was 70.6 +/- 8.9 years and, median FVC (%) was 72.1 +/- 18.7 at the initiation of first-line antifibrotics. The most common reason for the switch was disease progression (56%) followed by severe adverse effects (SAEs) (44%). SAEs were significantly less observed after the switch compared before the switch (43.9% vs12.1%, respectively, p < 0.001). Eighteen patients had adverse effects due to second-line antifibrotics. Among these patients, 10 had mild adverse effects and 8 had severe adverse effects. While there was no change in the FVC (%) values in 30.3% patients 12 months after the first-line antifibrotic treatment (before the switch), there was no change in the FVC (%) values in 40% patients at the end of 12 months after the switch. Fourteen patients (42.4%) who received antifibrotic treatment before the switch had more than 10% decline in FVC (%) at the end of 12 months. Eight patients (32.0%) had 10% or more decline in FVC (%) 12 months after the switch.Conclusion: Patients with IPF who do not tolerate first-line antifibrotic treatment or those showing disease progression despite treatment, switching antifibrotics may be a feasible management strategy.